Scientific Background: SB216763 is a potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor. It inhibits both human GSK-3α and GSK-3β. SB216763 has been shown to stimulate glycogen synthesis in human liver cells and mimic other actions of insulin. SB216763 is cell-permeable and ATP-competitive.
References: 1. Culbert A.A., et al. (2001) FEBS Letters. 507(3): 288–294.2. Coghlan M.P., et al. (2000) Chem. Biol. 7(10): 793–803.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.